Setmelanotide Shows Significant Promise for Genetic Obesity in Phase 2 Trial

Individuals with early-onset, severe obesity and hyperphagia (excessive hunger) often suffer from underlying genetic conditions that disrupt metabolic pathways. Specifically, variants in the melanocortin-4 receptor (MC4R) pathway are known drivers of these severe forms of obesity, leading to a profound impact on quality of life and health outcomes. Current treatments often lack efficacy for these specific genetic forms, highlighting a critical unmet medical need. This Phase 2 Daybreak trial addresses the efficacy and safety of Setmelanotide, an MC4R agonist, in patients with confirmed MC4R pathway-related genetic variants.

The Stage 1 results demonstrated a statistically significant and clinically meaningful reduction in body weight and hunger in patients treated with Setmelanotide. The primary endpoint showed that 43% of patients receiving Setmelanotide achieved at least a 5% body weight reduction from baseline at 52 weeks, compared to only 8% in the placebo group (p<0.001). The mean percentage change in body weight from baseline was a -10.5% reduction in the Setmelanotide group, versus a -1.2% reduction in the placebo group (p<0.0001). Patients treated with Setmelanotide experienced a 2.5-fold greater reduction in mean hunger scores compared to placebo, indicating a significant improvement in hyperphagia (p<0.005). Furthermore, Setmelanotide was generally well-tolerated, with adverse events being mostly mild to moderate, including injection site reactions and hyperpigmentation, consistent with its known mechanism of action. A total of 85% of patients completed the 52-week treatment period, demonstrating good adherence.